OTCMKTS:DNPUF - Sumitomo Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$7.70
+0 (0.00%)

This chart shows the closing price for DNPUF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sumitomo Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DNPUF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DNPUF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Sumitomo Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.70.

This chart shows the closing price for DNPUF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Sumitomo Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/10/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/23/2022CitigroupDowngradeBuy ➝ Neutral
8/16/2021Jefferies Financial GroupUpgradeHold ➝ Buy
6/14/2021Jefferies Financial GroupDowngradeBuy ➝ Hold
9/24/2019Jefferies Financial GroupInitiated CoverageBuy
(Data available from 8/10/2017 forward)

News Sentiment Rating

-0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/13/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/12/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/10/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.

Sumitomo Pharma

Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
Read More

Today's Range

Now: $7.70
Low: $7.70
High: $7.70

50 Day Range

MA: $8.06
Low: $7.60
High: $8.67

52 Week Range

Now: $7.70
Low: $7.60
High: $17.40

Volume

N/A

Average Volume

1,531 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Sumitomo Pharma?

The following Wall Street research analysts have issued stock ratings on Sumitomo Pharma in the last twelve months: Citigroup Inc., and Jefferies Financial Group Inc..
View the latest analyst ratings for DNPUF.

What is the current price target for Sumitomo Pharma?

0 Wall Street analysts have set twelve-month price targets for Sumitomo Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Sumitomo Pharma in the next year.
View the latest price targets for DNPUF.

What is the current consensus analyst rating for Sumitomo Pharma?

Sumitomo Pharma currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DNPUF will outperform the market and that investors should add to their positions of Sumitomo Pharma.
View the latest ratings for DNPUF.

What other companies compete with Sumitomo Pharma?

How do I contact Sumitomo Pharma's investor relations team?

Sumitomo Pharma's physical mailing address is 2-6-8 Dosho-machi, Osaka, 541-0045. The company's listed phone number is 81 6 6203 5321. The official website for Sumitomo Pharma is www.ds-pharma.com. Learn More about contacing Sumitomo Pharma investor relations.